Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology

NCT04731103 is registered in ClinicalTrials.gov with University of Edinburgh as lead sponsor.

NCT NCT04731103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04731103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology
Lead sponsor
University of Edinburgh
Phase
Phase 2
Overall status
Completed
Start date
August 24, 2022
Completion date
March 11, 2024
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aicardi-goutières syndrome